Education
About Us
Working with TipRanks
Follow Us
TScan Therapeutics (TCRX)
NASDAQ:TCRX
TCRX Stock Chart & Stats
$0.96
-$0.17(-5.65%)
At close: 4:00 PM EST
$0.96
-$0.17(-5.65%)
Day’s Range― - ―
52-Week Range$0.88 - $2.57
Previous CloseN/A
Volume150.47K
Average Volume (3M)456.88K
Market Cap
$54.56M
Enterprise Value-$22.22M
Total Cash (Recent Filing)$184.45M
Total Debt (Recent Filing)$95.62M
Price to Earnings (P/E)―
Beta2.01
Next Earnings
Mar 11, 2026EPS Estimate
-0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.28
Shares Outstanding52,471,405
10 Day Avg. Volume447,562
30 Day Avg. Volume456,876
Financial Highlights & Ratios
PEG Ratio0.17
Price to Book (P/B)1.41
Price to Sales (P/S)120.90
P/FCF Ratio-2.97
Enterprise Value/Market Cap-0.41
Enterprise Value/Revenue-2.64
Enterprise Value/Gross Profit-2.90
Enterprise Value/Ebitda0.16
Forecast
1Y Price Target
$6.33Price Target Upside559.38% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyUpdated ALLOHA Phase 1 results show a notably lower relapse rate for TSC-101 versus control with encouraging relapse‑free and overall survival trends, indicating potential meaningful benefit in the transplant setting.
Manufacturing And Commercial ReadinessAdoption of a 12-day commercial-ready manufacturing process shortens production time, reduces cost of goods, and yields robust T-cell product sufficient for higher dose levels and possible retreatment, supporting scalable commercialization.
Regulatory ProgressFDA alignment on a pivotal trial design for TSC-101 provides regulatory clarity and materially de-risks the path toward registration, supporting a clearer approval pathway.
Bears Say
Development Timeline RiskRegulatory requests for a lead-in manufacturing assessment and fixed-dose evaluation create operational hurdles that delay pivotal study initiation and extend the timeline to potential approval.
Financial RunwayHigh annualized cash burn and a limited cash runway prompted a workforce reduction to conserve capital, raising the risk of future financing needs or dilution if development timelines extend.
Pipeline Concentration RiskPausing the PLEXI-T solid tumor study and deprioritizing in-house TCR-T programs narrows the pipeline and removes potential near-term data catalysts, concentrating commercial and clinical risk on the heme program.
TScan Therapeutics News
TCRX FAQ
What was TScan Therapeutics’s price range in the past 12 months?
TScan Therapeutics lowest stock price was $0.88 and its highest was $2.57 in the past 12 months.
What is TScan Therapeutics’s market cap?
TScan Therapeutics’s market cap is $54.56M.
When is TScan Therapeutics’s upcoming earnings report date?
TScan Therapeutics’s upcoming earnings report date is Mar 11, 2026 which is in 33 days.
How were TScan Therapeutics’s earnings last quarter?
TScan Therapeutics released its earnings results on Nov 12, 2025. The company reported -$0.28 earnings per share for the quarter, beating the consensus estimate of -$0.334 by $0.054.
Is TScan Therapeutics overvalued?
According to Wall Street analysts TScan Therapeutics’s price is currently Undervalued.
Does TScan Therapeutics pay dividends?
TScan Therapeutics does not currently pay dividends.
What is TScan Therapeutics’s EPS estimate?
TScan Therapeutics’s EPS estimate is -0.27.
How many shares outstanding does TScan Therapeutics have?
TScan Therapeutics has 52,471,405 shares outstanding.
What happened to TScan Therapeutics’s price movement after its last earnings report?
TScan Therapeutics reported an EPS of -$0.28 in its last earnings report, beating expectations of -$0.334. Following the earnings report the stock price went down -2.459%.
Which hedge fund is a major shareholder of TScan Therapeutics?
Currently, no hedge funds are holding shares in TCRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
TScan Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.33 (559.38% Upside)
$6.33 (559.38% Upside)
Blogger Sentiment
Bullish
TCRX Sentiment 100%
Sector Average 69%
Sector Average 69%
Insider Transactions
Bought Shares
Worth $144.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 6.2%
Last 30 Days ▼ 7.5%
Last 30 Days ▼ 7.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-60.45%
12-Months-Change
Fundamentals
Return on Equity
-76.44%
Trailing 12-Months
Asset Growth
-24.65%
Trailing 12-Months
Company Description
TScan Therapeutics
TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation; and TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. The company is also developing vaccines for infectious diseases, such as SARS-CoV-2. It has a collaboration and license agreement with Novartis Institutes for BioMedical Research, Inc., to identify novel cancer antigens from the T cells of patients with a certain specific type of cancer. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
TCRX Stock 12 Month Forecast
Average Price Target
$6.33
▲(559.38% Upside)
Technical Analysis
Zentalis Pharmaceuticals
―
ALX Oncology Holdings
―
Inhibikase Therapeutics
―
Surrozen
―
Instil Bio
―
Ownership Overview
20.34% Insiders
6.15% Mutual Funds
0.02% Other Institutional Investors
69.32% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---